Abstract：
Plantar warts are common skin lesions that continue to represent a therapeutic challenge. They are still resistant to therapy and are highly recurrent, despite the diverse number of treatments available. Therapies targeting vasculature, such as pulsed dye laser, have been used successfully in the treatment of plantar warts. Polidocanol, a detergent sclerosant approved for the sclerotherapy of incompetent and dilated saphenous veins, has also been used as an off-label therapy for a wide range of skin conditions with vascular components such as hemangiomas and pyogenic granuloma. The current, open-label, prospective, pilot study aimed to evaluate the safety and efficacy of the intralesional polidocanol 3% in the treatment of plantar warts. Twenty patients (11 females and 9 males), with plantar warts, aged 12-50 years received biweekly sessions of intralesional polidocanol 3% until complete clearance or for a maximum of 6 sessions. Response to treatment was graded as complete (100% clearance), partial (50-99%), and no response (< 50%). At the end of the study, 12 (60%) patients achieved complete clearance of their warts after 1-5 sessions, 5 (25%) patients had only partial response, and 3 (15%) patients did not achieve any clearance of their warts. The procedure was largely tolerable by patients. Pain at the injection site and bruises were reported by 9 (45%) and 2 (10%) patients, respectively. Both side effects resolved spontaneously and completely within a few days. The findings of the current study suggest that intralesional injection of 3% polidocanol in biweekly sessions may be a safe, effective, and tolerable method for the treatment of plantar warts.
摘要：
足底疣是常见的皮肤病变，继续代表着治疗挑战。他们仍然对治疗有抵抗力，并且高度复发，尽管有各种各样的治疗方法。针对脉管系统的疗法，如脉冲染料激光器，已成功用于治疗足底疣。Polidocanol,一种洗涤剂硬化剂，被批准用于无能力和扩张的隐静脉的硬化治疗，还被用作具有血管成分的广泛皮肤病症如血管瘤和化脓性肉芽肿的标签外疗法。当前,开放标签，prospective,初步研究旨在评估3％脊髓灰质炎治疗足底疣的安全性和有效性。20名患者（11名女性和9名男性），有足底疣，12-50岁的人每两周接受一次3％的脊髓灰质炎，直到完全清除或最多6次。对治疗的反应分级为完全（100%清除），部分（50-99%），无反应（<50%）。在研究结束时,12（60％）患者在1-5个疗程后完全清除了疣，5（25％）患者仅有部分反应，和3（15％）患者没有实现任何疣的清除。该程序在很大程度上是患者可以忍受的。9例（45%）和2例（10%）患者报告了注射部位疼痛和瘀伤，分别。两种副作用在几天内自发和完全消失。当前研究的结果表明，每两周一次的病灶内注射3％的脊髓灰质炎可能是安全的，有效,治疗足底疣的方法。
